X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (334) 334
Publication (54) 54
Book / eBook (2) 2
Book Chapter (2) 2
Book Review (2) 2
Conference Proceeding (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (194) 194
oncology (151) 151
female (143) 143
middle aged (143) 143
male (135) 135
aged (128) 128
index medicus (126) 126
adult (122) 122
treatment outcome (77) 77
aged, 80 and over (69) 69
cancer (67) 67
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
neoplasms - drug therapy (50) 50
chemotherapy (46) 46
antineoplastic combined chemotherapy protocols - adverse effects (43) 43
article (43) 43
clinical trials (43) 43
antineoplastic agents - therapeutic use (40) 40
therapy (40) 40
research (39) 39
mutation (38) 38
survival (36) 36
young adult (36) 36
adolescent (35) 35
pharmacology & pharmacy (35) 35
solid tumors (35) 35
prognosis (33) 33
retrospective studies (32) 32
care and treatment (31) 31
disease-free survival (31) 31
neoplasms - genetics (30) 30
hematology (29) 29
neoplasms - pathology (28) 28
patients (27) 27
antineoplastic combined chemotherapy protocols - administration & dosage (26) 26
bevacizumab (25) 25
tumors (25) 25
medicine & public health (24) 24
survival analysis (24) 24
pharmacology/toxicology (23) 23
drug therapy (22) 22
neoplasms (22) 22
molecular targeted therapy (21) 21
survival rate (20) 20
toxicity (20) 20
kaplan-meier estimate (19) 19
maximum tolerated dose (18) 18
neoplasm metastasis (18) 18
phase i (18) 18
neoplasms - mortality (17) 17
phase i trial (17) 17
breast-cancer (16) 16
clinical trials, phase i as topic (16) 16
melanoma (16) 16
metastasis (16) 16
phosphatidylinositol 3-kinases - genetics (16) 16
targeted therapy (16) 16
abridged index medicus (15) 15
antineoplastic agents - adverse effects (15) 15
colorectal-cancer (15) 15
cytarabine - administration & dosage (15) 15
drug administration schedule (15) 15
liver neoplasms - secondary (15) 15
neoplasm staging (15) 15
vidarabine - analogs & derivatives (15) 15
cancer patients (14) 14
cell lung-cancer (14) 14
combination (14) 14
liver neoplasms - drug therapy (14) 14
lung-cancer (14) 14
patient outcomes (14) 14
research paper (14) 14
resistance (14) 14
antibodies, monoclonal, humanized (13) 13
cancer research (13) 13
cancer therapies (13) 13
class i phosphatidylinositol 3-kinases (13) 13
complications and side effects (13) 13
fludarabine (13) 13
follow-up studies (13) 13
immunotherapy (13) 13
remission induction (13) 13
rituximab (13) 13
studies (13) 13
antibodies, monoclonal - administration & dosage (12) 12
chronic lymphocytic leukemia (12) 12
dosage and administration (12) 12
dose-response relationship, drug (12) 12
health aspects (12) 12
leukemia (12) 12
leukemia, lymphocytic, chronic, b-cell - drug therapy (12) 12
organoplatinum compounds - administration & dosage (12) 12
personalized medicine (12) 12
proto-oncogene proteins b-raf - genetics (12) 12
risk factors (12) 12
angiogenesis (11) 11
antibodies, monoclonal, humanized - administration & dosage (11) 11
child (11) 11
clinical trials as topic (11) 11
disease progression (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 04/2016, Volume 13, Issue 4, pp. 207 - 208
Journal Article
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 2009, Volume 5, Issue 1, pp. 281 - 289
Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for... 
Chronic myeloid leukemia | Tyrosine kinase inhibitor | Dasatininb | BCR-ABL | Leukemia | Mutation | dasatininb | chronic myeloid leukemia | tyrosine kinase inhibitor
Journal Article
Cancer, ISSN 0008-543X, 01/2004, Volume 100, Issue 2, pp. 342 - 349
BACKGROUND. The goal of the current study was to assess the toxicity, safety, and efficacy of pentostatin in patients with T-cell lymphoid malignancies.... 
Adenosine | Deaminase | Inhibitor | Lymphomas | T cells | deaminase | lymphomas | INTERFERON ALFA-2A | FOLLOW-UP | 2'-DEOXYCOFORMYCIN | SEZARY-SYNDROME | PRIMARY CUTANEOUS LYMPHOMAS | adenosine | LEUKEMIA PATIENTS | THERAPY | inhibitor | ONCOLOGY | DISEASE | EORTC CLASSIFICATION | MYCOSIS FUNGOIDES/SEZARY-SYNDROME
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 7, p. e22769
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 04/2016, Volume 13, Issue 4, p. 207
Journal Article
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 10/2018, Volume 6, Issue 1, pp. 72 - 108
PurposeTo develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of... 
CHECKPOINT INHIBITORS | RESPONSE CRITERIA | RANDOMIZED-TRIALS | ONCOLOGY | ADVANCED MELANOMA | GUIDELINES | TUMOR RESPONSE | POOLED ANALYSIS | IMMUNOLOGY | NIVOLUMAB PLUS IPILIMUMAB | ADVERSE EVENTS | TREATMENT FAILURE | Care and treatment | Usage | Cell death | Analysis | Clinical trials | Research | Licensing, certification and accreditation | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2019, Volume 37, Issue 1, pp. 72 - 80
PurposeTo develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of... 
SURVIVAL | THERAPY | RESPONSE CRITERIA | ONCOLOGY | GUIDELINES | TIME | NIVOLUMAB PLUS IPILIMUMAB | ADVERSE EVENTS | CHALLENGES | TREATMENT FAILURE | CLINICALTRIALS.GOV | Index Medicus | ASCO Special
Journal Article
Archives of pathology & laboratory medicine, ISSN 0003-9985, 10/2018, Volume 142, Issue 10, pp. 1242 - 1253
Journal Article
Nutrition and Cancer, ISSN 0163-5581, 02/2012, Volume 64, Issue 2, p. 206
The association between body composition parameters and toxicity from hepatic arterial infusion (HAI) chemotherapy regimens has not been analyzed. We assessed... 
Chemotherapy | Toxicity | Colorectal cancer | Metastasis | Patients
Journal Article